Chengdu Easton Biopharmaceuticals Co Ltd - Asset Resilience Ratio

Latest as of March 2026: 34.30%

Chengdu Easton Biopharmaceuticals Co Ltd (688513) has an Asset Resilience Ratio of 34.30% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.

Liquid Assets

CN¥1.30 Billion

≈ $189.58 Million USD Cash + Short-term Investments

Total Assets

CN¥3.78 Billion

≈ $552.76 Million USD All company assets

Resilience Assessment

Very High

Financial Resilience Level

Asset Resilience Ratio Trend (2013–2025)

This chart shows how Chengdu Easton Biopharmaceuticals Co Ltd's Asset Resilience Ratio has changed over time. See Chengdu Easton Biopharmaceuticals Co Ltd free cash flow to debt ratio to measure the company's free cash flow as a share of total liabilities.

Liquid Assets Composition Over Time

This chart breaks down Chengdu Easton Biopharmaceuticals Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see 688513 market cap overview.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	CN¥0.00	0%
Short-term Investments	CN¥1.30 Billion	34.3%
Total Liquid Assets	CN¥1.30 Billion	34.30%

Asset Resilience Insights

Very High Liquidity: Chengdu Easton Biopharmaceuticals Co Ltd maintains exceptional liquid asset reserves at 34.30% of total assets.
This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
The company has significant short-term investments, indicating active treasury management.

Chengdu Easton Biopharmaceuticals Co Ltd Industry Peers by Asset Resilience Ratio

Compare Chengdu Easton Biopharmaceuticals Co Ltd's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Prostemics Co. Ltd KQ:203690	Biotechnology	0.31%
ORUM KQ:475830	Biotechnology	82.74%
TELIX Pharmaceuticals Ltd AU:TLX	Biotechnology	32.29%
TG Therapeutics Inc NASDAQ:TGTX	Biotechnology	4.72%
Green Cross Holdings Preference Shares KO:005257	Biotechnology	0.50%
Rocket Pharmaceuticals Inc NASDAQ:RCKT	Biotechnology	33.70%
NEWRON PHARMACEUT. EO-20 XETRA:NP5	Biotechnology	41.67%
Cybin Inc NEO:CYBN	Biotechnology	0.21%

Annual Asset Resilience Ratio for Chengdu Easton Biopharmaceuticals Co Ltd (2013–2025)

The table below shows the annual Asset Resilience Ratio data for Chengdu Easton Biopharmaceuticals Co Ltd.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2025-12-31	19.96%	CN¥758.00 Million ≈ $110.92 Million	CN¥3.80 Billion ≈ $555.75 Million	+6.65pp
2024-12-31	13.30%	CN¥452.35 Million ≈ $66.19 Million	CN¥3.40 Billion ≈ $497.55 Million	-8.86pp
2023-12-31	22.16%	CN¥741.78 Million ≈ $108.55 Million	CN¥3.35 Billion ≈ $489.74 Million	+5.05pp
2022-12-31	17.11%	CN¥516.36 Million ≈ $75.56 Million	CN¥3.02 Billion ≈ $441.56 Million	+0.76pp
2021-12-31	16.35%	CN¥453.84 Million ≈ $66.41 Million	CN¥2.78 Billion ≈ $406.11 Million	-6.17pp
2020-12-31	22.52%	CN¥570.00 Million ≈ $83.41 Million	CN¥2.53 Billion ≈ $370.34 Million	+21.34pp
2013-12-31	1.18%	CN¥3.00 Million ≈ $438.99K	CN¥254.86 Million ≈ $37.29 Million	--

pp = percentage points

About Chengdu Easton Biopharmaceuticals Co Ltd

SHG:688513 China Biotechnology

Market Cap

$1.18 Billion

CN¥8.06 Billion CNY

Market Cap Rank

#8193 Global

#1898 in China

Share Price

CN¥45.66

Change (1 day)

+0.26%

52-Week Range

CN¥41.53 - CN¥79.60

All Time High

CN¥79.60